Iodide symporter gene expression in human thyroid tumors

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• The Na+/I- symporter (NIS) is crucial for thyroid hormone synthesis and radioiodine uptake.
• Understanding NIS gene expression in thyroid tumors is vital for predicting treatment response.

Purpose of the Study:

• To investigate Na+/I- symporter (NIS) gene expression in various thyroid tumors.
• To correlate NIS expression with tumor type and metastatic potential.
• To assess the diagnostic and prognostic value of NIS gene expression in differentiated thyroid cancer.

Main Methods:

• Reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze NIS messenger ribonucleic acid (mRNA) expression.
• Dot blot analysis quantified NIS mRNA levels in primary tumors and metastases.
• Thyroid carcinomas and adenomas were analyzed, including papillary, follicular, and anaplastic types.

Main Results:

• NIS mRNA was expressed in most follicular adenomas and follicular thyroid cancers.
• NIS expression was reduced or absent in anaplastic thyroid cancers and some papillary thyroid cancers.
• Reduced NIS mRNA expression in primary tumors correlated with metastases and negative post-therapy 131I scans.
• Loss of NIS expression in metastases was an intrinsic defect of primary cancer cells, not dedifferentiation.

Conclusions:

• Loss of NIS gene expression is a significant finding in differentiated thyroid cancer, particularly in cases with metastases.
• This defect is an intrinsic molecular alteration of the primary tumor.
• Early detection of absent NIS gene expression in primary thyroid cancer may improve patient management and treatment strategies.